1. Keytruda (Pembrolizumab): first PD-1 inhibitor approved for previously treated unresectable or metastatic melanoma.;Raedler;Am Health Drug Benefits,2015
2. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.;McDermott;Drugs Today (Barc),2015
3. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.;Villadolid;Transl Lung Cancer Res,2015
4. Anti-PD1-induced collagenous colitis in a melanoma patient.;Baroudjian;Melanoma Res,2016